• Mashup Score: 1

    Published: May 19, 2025Updated: June 2, 2025Written by: Lukas Harnisch-WeidauerJyoti Bajpai, MD, DM, an oncologist practicing in the Apollo Hospital network in India, is well versed in treating rare cancers, but when she encountered someone with prostate cancer who was undergoing gender-affirming hormone replacement therapy, she found surprisingly little data to inform her approach.  The … Read more

    Tweet Tweets with this article
    • .@shail_maingi, MD, brought her experience in LGBTQ+ inclusive cancer care to India, supporting efforts to better serve LGBTQ+ patients. Read how this global effort is supporting more inclusive care: https://t.co/9TJTdQWQcC

  • Mashup Score: 7

    Published: May 7, 2025Written by: Dana-Farber Editorial TeamMedically Reviewed By: Ting Bao, MD, MSCold plunges, the act of immersing the body in cold water for therapeutic benefit, have been used for centuries — from vinterbading in Scandinavia (swimming in cold water during winter months) to misogi in Japan (a Shinto practice of purifying the body … Read more

    Tweet Tweets with this article
    • Cold plunges are gaining popularity for their reported benefits, from reducing inflammation to aiding muscle recovery and boosting mood. The positive effects are numerous — but can cold plunges prevent or treat cancer? Learn what the research says: https://t.co/JWO6qki1Nl https://t.co/F7eytL0TFC

  • Mashup Score: 8

    When employees are satisfied in their work environment, the results speak for themselves. Newsweek and Plant-A Insights Group present America’s Greatest Workplaces 2025, recognizing companies that lead the way in employee engagement.

    Tweet Tweets with this article
    • We’re proud to be recognized by @Newsweek as one of America’s Greatest Workplaces in Healthcare 2025! Thank you to our incredible staff who makes Dana-Farber such a special place to work. View the full list here: https://t.co/Rd6yGqNIj3

  • Mashup Score: 21

    Antibody-drug conjugates are targeted agents that package cancer drugs for special delivery to tumor cells to eliminate them.

    Tweet Tweets with this article
    • Antibody-drug conjugates are a targeted form of cancer therapy designed to expose tumor cells to the full force of cancer drugs while sparing normal cells from damage, potentially reducing the side effects often associated with cancer therapy. Learn more: https://t.co/tYG69lNXlC https://t.co/U1HkQ9G7MO

  • Mashup Score: 36

    At ASCO 2025, Dana-Farber Cancer Institute researchers are leading four studies with compelling and potentially practice changing results in colorectal cancer and breast cancer. Investigators will also present clinical trial results that support future research into new strategies for the treatment of rare and aggressive forms of cancer and new approaches to de-escalate treatment and improve quality of life.

    Tweet Tweets with this article
    • We’re thrilled to be attending the 2025 American Society of Clinical Oncology (@ASCO) Annual Meeting, where more than 115 studies led by Dana-Farber affiliated researchers will be presented. View oral and poster presentations and the press program here: https://t.co/IKFHh6MYcK https://t.co/BBFA0M0FIQ

  • Mashup Score: 27

    A common gastrointestinal cancer drug that crosses the blood-brain barrier showed promise in patients with aggressive high-grade gliomas.

    Tweet Tweets with this article
    • May is Brain Cancer Awareness Month. New research from the lab of @FilbinMariella, MD, PhD, suggests that avapritinib, an FDA-approved drug used to treat GI tumors, could also treat high-grade gliomas. Learn more. https://t.co/NyUXxiLKo6

  • Mashup Score: 28

    One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program at Dana-Farber Cancer Institute is to provide resources and information to help guide patients through many situations and decisions. 

    Tweet Tweets with this article
    • Join Nancy Lin, MD (@nlinmd) & Sara Tolaney, MD, MPH (@stolaney1) via Zoom for the 1st webinar of the ’24-‘25 EMBRACE #MetastaticBreastCancer Forum Series of free programs for patients on 10/11. Learn about advances & connect with others w #MBC @drsarahsam https://t.co/L4jQHqVjWD https://t.co/PthXulbeFe

  • Mashup Score: 23

    Learn the truth behind the myths about clinical trials. Understanding these can help patients make informed decisions about participation.

    Tweet Tweets with this article
    • Clinical trials drive progress in cancer treatment, yet only 3% of cancer patients in the U.S. participate. Misinformation plays a big role. Swipe through to learn the truth about clinical trials and why they matter for advancing cancer care. Learn more: https://t.co/chp5ChMNjw https://t.co/ZEq0SeQdRn